A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy

PharmacoEconomics

Volumn 34, Issue 10, 2016, Pages 1023-1038

  Tappenden, Paul ^a   Ren, Shijie ^a   Archer, Rachel ^a   Harvey, Rebecca ^a   James, Marrissa Martyn St ^a   Basarir, Hasan ^a   Stevens, John ^a   Lobo, Alan ^b   Hoque, Sami ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c BARTS HEALTH NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; AZATHIOPRINE; GOLIMUMAB; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PREDNISOLONE; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; ADULT DISEASE; ARTICLE; BIOLOGICAL THERAPY; COLON RESECTION; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE CONTROL; DISEASE SEVERITY; ECONOMIC EVALUATION; ELECTIVE SURGERY; FEMALE; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MARKOV CHAIN; META ANALYSIS (TOPIC); NATIONAL HEALTH SERVICE; PATIENT HISTORY OF COLECTOMY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SURGICAL MORTALITY; SYSTEMATIC REVIEW (TOPIC); TREATMENT FAILURE; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; COLITIS, ULCERATIVE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMIC MODEL; ECONOMICS; PATHOPHYSIOLOGY; PROCEDURES; UNITED KINGDOM;

ADALIMUMAB; ADULT; ANTIBODIES, MONOCLONAL; COLECTOMY; COLITIS, ULCERATIVE; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFLIXIMAB; MALE; MARKOV CHAINS; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; TUMOR NECROSIS FACTOR-ALPHA; UNITED KINGDOM;

EID: 84964489945     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-016-0409-9     Document Type: Article

References (37)

1. National Institute for Health and Care Excellence. Ulcerative colitis: Management in adults, children and young people. NICE Clinical Guideline Number 166. London: NICE; 2013, pp 1–37.
2. Ford AC, Moayyedi P, Hanauer SB. Ulcerative colitis. Br Med J 2013; 346. http://www.bmj.com/content/346/bmj.f432.long. Accessed 01 May 2014.
3. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut. 2004;53(10):1471–8.
4. Bayless TM, Hanauer SB. Advanced therapy in inflammatory bowel disease: volume 1—IBD and ulcerative colitis. 3rd ed. Shelton: Connecticut: People’s Medical Publishing House—USA; 2011.
5. Royal College of Physicians. Report of the results for the national clinical audit of adult inflammatory bowel disease inpatient care in the UK. 1-67. London: RCP; 2012, p. 1–68.
6. European Medicines Agency. Summary of product characteristics—infliximab. London: EMA; 2009. p. 1–56.
7. European Medicines Agency. Summary of product characteristics—adalimumab. London: EMA; 2009. p. 1–292.
8. European Medicines Agency. Summary of product characteristics—golimumab. London: EMA; 2009. p. 1–199.
9. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olsen A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76.
10. Reinisch W, Sandborn WJ, Hommes DW, D’Haens G, Hanauer SB, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780–7.
11. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D’Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257–65.
12. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85–95.
13. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):96–109.
14. Suzuki Y, Motoya S, Hanai H, Matsumoto T, Hibi T, Robinson AM, et al. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2014;49(2):283–94.
15. Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392–400.
16. Probert CS, Hearing SD, Schreiber S, Kühbacher T, Ghosh S, Arnott ID, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52(7):998–1002.
17. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. London: NICE; 2013. p. 1–102.
18. Archer R, Tappenden P, Ren S, Martyn St-James M, Harvey R, Basarir H et al. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy: Clinical effectiveness systematic review and economic model. Final report to the National Institute for Health and Care Excellence. Sheffield: University of Sheffield 2014, p. 1–438.
19. Cooney RM, Warren BF, Altman DG, Abreu MT, Travis SP. Outcome measurement in clinical trials for ulcerative colitis: towards standardisation. Trials 2007;8(17). http://www.trialsjournal.com/content/8/1/17. Accessed 01 June 2014.
20. Woehl A, Hawthorne AB, McEwan P. The relation between disease activity, quality of life and health utility in patients with ulcerative colitis. Gut. 2008;57(Suppl1):A153.
21. Arseneau KO, Sultan S, Provenzale DT, Onken J, Bickston SJ, Foley E, et al. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? Clin Gastroenterol Hepatol. 2006;4(9):1135–42.
22. Solberg IC, Lygren I, Jahnsen J, Aadland E, Høie O, Cvancarova M, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44(4):431–40.
23. Arai K, Koganei K, Kimura H, Akatani M, Kitoh F, Sugita A, et al. Incidence and outcome of complications following restorative proctocolectomy. Am J Surg. 2005;190(1):39–42.
24. BMJ Group and the Royal Pharmaceutical Society of Great Britain. Br Natl Formul. 2014. https://www.medicinescomplete.com/mc/bnf/current/. Accessed 01 May 2014.
25. Tsai HH, Punekar YS, Morris J, Fortun P. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Aliment Pharmacol Therapeut. 2008;28(10):1230–9.
26. Merck, Sharp, Dohme. Manufacturer’s submission of evidence to the National Institute for Health and Care Excellence: Infliximab. Hertfordshire: MSD; 2014.
27. Department of Health. NHS Reference Costs 2012/13. London: DH. https://www.gov.uk/government/publications/nhs-reference-costs-2012-to-2013. Accessed 04 May 2014.
28. Buchanan J, Wordsworth S, Ahmad T, Perrin A, Vermeire S, Sans M, et al. Managing the long term care of inflammatory bowel disease patients: The cost to European health care providers. J Crohn Colitis. 2011;5(4):301–16.
29. Dias S, Welton N, Sutton A, Ades A. NICE Decision Support Unit Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. Sheffield: University of Sheffield; 2011. p. 1–98.
30. Thomas A, O’Hara B, Ligges U, Sturtz S. Making BUGS open. R News. 2015;6:12–7.
31. Office for National Statistics. Interim life tables 2009–2011. 2013. http://www.ons.gov.uk/ons/rel/lifetables/interim-life-tables/2009-2011/stb-2009-2011.html. Accessed 05 May 2014.
32. Swinburn P, Elwick H, Bean K, Curry A, Patel S, Bodger K, et al. The impact of surgery on health related quality of life in ulcerative colitis. Gut. 2012;61(Suppl2):A237.
33. Van der Valk ME, Mangen MJ, Dijkstra G, Bodegraven AA, Fiddler H, De Jong DJ et al. Is there a difference in quality of life and costs between ulcerative colitis patients with a pouch or an ileostomy? Dig Dis Wk; 2012.
34. Richards DM, Hughes SA, Irving MH, Scott NA. Patient quality of life after successful restorative proctocolectomy is normal. Colorectal Dis. 2001;3(4):223–6.
35. Kuruvilla K, Osler T, Hyman NH. A comparison of the quality of life of ulcerative colitis patients after IPAA vs ileostomy. Dis Colon Rectum. 2012;55(11):1131–7.
36. Curtis L. Unit costs of health and social care 2014. 1–294. Personal Social Services Research Unit: Kent; 2014.
37. Xie F, Blackhouse G, Assasi N, Gaebel K, Robertson D, Goeree R. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost Eff Resour Alloc. 2009;7:20.